ATM and mantle cell lymphoma: In Mantle Cell Lymphoma (MCL) cell lines, the combination of the ATM inhibitor KU-60019 with the histone deacetylase (HDAC) inhibitor Romidepsin (34) was found to be synergistic via downregulation of the CDK inhibitor p21 (35).